Non-Dopaminergic Therapies
Authors:
Open Access
- 18 December 2018
- journal article
- review article
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 8 (s1) , S73-S78
Abstract
Currently all aspects of Parkinson’s disease (PD) treatment are less than ideal and would benefit from new interventions. We focus on problems associated with brain neurotransmitters amenable to more specific subreceptor and temporal manipulation. In addition, we consider potentially treatable CNS non-PD co-pathologies or co-morbidities that may exacerbate progression of various aspects of PD.Keywords
This publication has 29 references indexed in Scilit:
- Prevalence, Determinants, and Effect on Quality of Life of Freezing of Gait in Parkinson DiseaseJAMA Neurology, 2014
- Extra‐nigral pathological conditions are common in Parkinson's disease with freezing of gait: An in vivo positron emission tomography studyMovement Disorders, 2014
- Sleep Drives Metabolite Clearance from the Adult BrainScience, 2013
- St.John'sWort Reduces Beta‐Amyloid Accumulation in a Double TransgenicAlzheimer's Disease Mouse Model—Role ofP‐GlycoproteinBrain Pathology, 2013
- A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid βScience Translational Medicine, 2012
- Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humansProceedings of the National Academy of Sciences, 2011
- Motor complications in Parkinson's disease: Ten year follow‐up studyMovement Disorders, 2010
- Modes and Models of Forebrain Cholinergic Neuromodulation of CognitionNeuropsychopharmacology, 2010
- Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2005
- A new dynamic model of the cortico-basal ganglia loop2004